
References

11. Hobbs FD, Fitzmaurice DA, Mant J

25. Frykman V, Beerman B, Ryden L

12. Nieuwlaat R, Olsson SB, Lip GY

27. Fuster V, Ryden LE, Cannom DS

28. Cairns JA, Connolly S, McMurtry S

33. Lip GY, Agnelli G, Thach AA

30. Groene O, Lombarts M, Klazinga N

21. Evers SM, Struijs JN, Ament AJ

20. Rodgers H, Sudlow M, Dobson R


31. Winter Y, Wolfram C, Schaeg M


Ann Intern Med


J Neurol Neurosurg Psychiatry

2006;38:354-60. J Neurol Neurosurg Psychiatry


Europace


Circulation


1987;147:1561-4.

PatientCharter

Bayer Pharma AG provided funding for a secretariat to support the committee.

The Charter has been developed independently by a committee of patient groups. Bayer Pharma AG provided funding for a secretariat to support the committee.

Global Atrial Fibrillation Patient Charter
Atrial Fibrillation (AF) is one of the most important risk factors for stroke. People with AF are at increased risk from blood clots and are five times more likely to have a stroke compared to the general population. AF accounts for 20% of all ischemic strokes. Many AF-related strokes could be prevented by earlier diagnosis, access to appropriate treatment and improved management.

This Charter recommends clear solutions that policymakers, healthcare providers, payers and national governments can implement to improve the lives of people with AF and at risk for AF-related stroke.